This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

The Fight is on​​​​​​​

Across the world, cases of Gram-negative hospital acquired and ventilator associated pneumonia are on the rise1-3

​​The cause? Multi-drug resistant pathogens1-3

In the short videos below you will: 
•    Hear about the experience of contracting HAP/VAP
•    Learn what you can do to fight it in your clinical setting 
•    Discover some of the incentives already underway to improve and protect global public health from this threat

​​​​​​​HAP/VAP accounts for around 22% of all Hospital-acquired Infections

Putting HAP/VAP under the microscope

"Pneumonia was different: I felt like it controlled me. I couldn't breathe, I felt like I was drowning."

Hear about patient John Sperzel's experience

Contact us

“The longer the delay for an appropriate treatment, the higher the mortality rate.”4,5

Listen to Dr Philippe Montravers

Download the audio

“How can we work together to address the growing threat of multidrug-resistant Gram-negative infections?”

Listen to Paurus Irani MD

Download the audio

50-80% of HAP/VAP infections are caused by MDR Gram-negative bacteria

of HAP/VAP infections are caused by MDR Gram-negative bacteria. The most common of these pathogens are P. aeruginosa, ESBL-producing Enterobacteriaceae, and Carbapenem-resistant Enterobacteriaceae (CRE)3,6

Act swiftly and appropriately

Early appropriate treatment, based on local epidemiology and risk factors for MDR pathogens, is extremely important3

HAP/VAP​​​​​​​

The Resident Threat

of all Hospital-Acquired Infections HAP/VAP account for
​​​​​​​
HAP/VAP account for around 22% of all Hospital-acquired infections​​​​​​​

​​​​​

Attacking Your Most Severely Ill Patients

Nosocomial Pneumonia Cases - mostly VAP- occur in the ICU5
​​​​​​​​​​​​​​​​​​​​​​​​
Around 1/3 mostly VAP cases occur in the ICU​​​​​​​

Prescribing information

​​​​​​​Zavicefta (ceftazidime and avibactam) 2g/0.5 g Powder for Concentrate for Solution for Infusion

References
  1. Morris S, Cerceo E. Antibiotics (Basel) 2020;9:196.
  2. Peleg AV, Hooper DC. N Engl J Med 2010; 362:1804-13.
  3. Cillóniz C, et al. Curr Opin Infect Dis 2019;32:656-62.
  4. Kalil AC, et al. Clin Infect Dis 2016;63:E61-E111.
  5. Torres A, et al. Eur Respir J 2017;50:1700582.
  6. Zaragoza R, et al. Critical Care 2020;24:383.
PP-ZVA-GBR-1289. October 2021

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No